KRAS and non-small cell lung carcinoma: Patients with aNSCLC without a KRAS alteration but exhibiting other oncogenic drivers with available approved targeted therapies, had significantly better OS than patients with NSCLC harboring KRAS G12C mutations (27 vs. 11 mos, HR 0.55, 95% CI 0.49–0.63, p < 0.001).